



Next Generation Pharmaceutical Summit • US
 26 - 28 APRIL 2010 • The Boulders Resort and Golden Door Spa • Arizona
www.ngpsummit.com



KEYNOTE SPEAKER



Mark Powell – Keynote Speaker
 SVP and Head of Pharmaceutical Development

GOLD SPONSOR



SILVER SPONSORS



SPONSORS



TESTIMONIALS...

“A great networking opportunity and a great change to meet vendors in an unpressured setting. Much better venue for learning what they do”

Daniel Adelman, SVP Development & CMO, Alvine Pharmaceuticals

“Very enlightening experience being able to network with the leaders of pharma”

Bob Kimbro, Pfizer

“I met well informed, thoughtful colleagues and I gained valuable insights”

Mark Goldberg, SVP Global Therapeutic Group Head Oncology, Personalised Genetic Health, Genzyme

“The summit provides a unique forum for open and collegial discussion of industry challenges and potential solution thereof.”

William Olsen, SVP, Research & Development, Progenics



pharmiweb.com

Pharmaceuticals | Clinical Research | M&A/Int'l | Sales/Marketing | Healthcare | Recruitment | Pharmacy | Medical Devices

Business Intelligence | Turnkey Business Intelligence into Intelligent Business | **NGP** | **NGP** | **NGP**

Feature

Fighting talk unites Pharma
Posted on 17 Apr 10

Summary

The NGP union, held in the Netherlands last week, saw over 50 visionaries gathered for the Supreme Court verdict against Myriad Genetics given on March 29th. They voted against their patent claims and a storm is brewing in the biotech community. The Court ruled that the patents should have never been granted because genes are "a law of nature." With the majority of industry outsiders in agreement, how will the pharmaceutical world react?

NGP Fighting talk unites Pharma

The NGP union, held in the Netherlands last week, saw over 50 visionaries gathered for the Supreme Court verdict against Myriad Genetics given on March 29th. They voted against their patent claims and a storm is brewing in the biotech community. The Court ruled that the patents should have never been granted because genes are "a law of nature." With the majority of industry outsiders in agreement, how will the pharmaceutical world react?

pharma financing

Pharmaceutical Careers
Continuation for the Pharmaceutical in Bologna (Italy) - Sign up

Pharmaceutical

Pharmaceutical
World Leading OpenSource OS Unlocks the power today!

epm news
European Pharmaceutical Manufacturer

HOME | NEWS | MAGAZINE | DIRECTORY | RESOURCE CENTRE | PARTNERS | EVENTS | JOB

Measurement and Validation Solutions for Pharmaceutical and Biotech Processing

SEARCH ARCHIVE NEWS BY: ARTICLES TITLE | PRODUCT CATEGORY | BY COMPANY | KEY

Fighting Talk Over Myriad Genetics Patents at NGP US Summit
April 2010

The NGP union, held in the Netherlands, saw over 50 visionaries gathered for the Supreme Court verdict against Myriad Genetics given on 29th March. They voted against their patent claims and a storm is brewing in the biotech community. The Court ruled that the patents should have never been granted because genes are "a law of nature." With the majority of industry outsiders in agreement, how will the pharmaceutical world react?

The NGP US summit (held by GDS International) has now been called as a reaction to the result, for the end of the month in Arizona. Jerry Lanctbury, EVP of Myriad Genetics, will lead a discussion on the day of the summit and the potential effects of it.

epm
Breaking

GeneVac
Independent gene and antibody

Search results for GDS International

3 **Fighting talk unites Pharma over patents on gene sequencing - Pharmaceutical and Biotechnology News - Pharma Letter**

Vote

Posted by [email] 17 days ago (http://www.thepharmaliter.com)

The Next Generation Pharmaceutical (NGP) Union, held in the Netherlands last week, saw over 50 drug industry leaders gathered for the Supreme Court verdict against Myriad Genetics given on March 29, which voted against the company's patent claims and, as

[Read More](#) | [Discuss](#) | [Buy!](#)

[Corporate](#) | [top us gds international myriad](#) | [All](#)

LOGI

Users

Passw

Remer

TOP



hospitalpharma.com™

THE ONLINE RESOURCE FOR HOSPITAL PHARMACY

- Home
- News
- Features
- Events
- Careers
- Press Releases
- Resources
- About Us

login

Areas of this site are restricted to registered users only. Please log in.

[Not Registered? Click here.](#)

[Forgot your Password?](#)

SEARCH:

[Resources](#) | [Features](#) | [Fighting talk unites Pharma...](#)

[submit a feature](#)

Fighting talk unites Pharma
13 Apr 10

[comment on this feature](#)
[send this to a friend](#)

Summary

The NGP union, held in the Netherlands last week saw over 50 visionaries gathered for the Supreme Court verdict against Myriad Genetics given on March 29th. They voted against their patent claims and a storm is brewing in the biotech community. The Court ruled that the patents should have never been granted because genes are a law of nature. With the majority of industry outsiders in agreement, how will the pharmaceutical world react?



NGP
Next Generation Pharmaceutical Summit

Fighting talk unites Pharma

The NGP union, held in the Netherlands last week saw over 50 visionaries gathered for the Supreme Court verdict.

the pharma letter

HOME | 30 DAY PREMIUM TRIAL | PHARMACEUTICALS | BIOTECHNOLOGY | GENERICS | EVENTS | COMPANIES | [SUBSCRIBE](#)

Keywords: Gene sequencing, Patents, NCP, Myriad Genetics

Fighting talk unites Pharma over patents on gene sequencing

Article | 15 April 2010

[Print This](#) [Share This](#)

The Next Generation Pharmaceutical (NGP) Union, held in the Netherlands last week, saw over 50 drug industry leaders gathered for the Supreme Court verdict against Myriad Genetics given on March 29, which voted against the company's patent claims and, as a result, a storm is brewing

Related Articles

[Biotechnology - political and legal intrigues, viewed by Rothman Research](#)

15 April 2010

[Recent decision outlawing gene patents has limited applicability, says NY patent attorney, Ted Sabety](#)

21 April 2010

[Five Chinese SFDA officials arrested for taking bribes](#)

20 April 2010

NewsRx™

[Subscriber login](#)

HOME | [FREE NEWSLETTERS](#) | [PRODUCTS](#) | [ARTICLE LIBRARY](#) | [ABOUT US](#) | [CONTACT](#)

Find what you are looking for

Fighting talk unites

All News

[SEARCH](#)



Fighting talk unites Pharma

[Printer-Friendly Version](#)

The NGP union, held in the Netherlands last week saw over 50 executives gathered for the Supreme Court verdict against Myriad Genetics given on March 29th. They voted against their patent claims and a storm is brewing in the biotech community. The Court ruled that the patents should have never been granted because genes are "a law of nature." With the majority of industry insiders in agreement, how will the pharmaceutical world react?

The NGP US summit (held by GDS International) has now been called as a reaction to the result, for the end of the month in Arizona. Jerry Lanchbury, CEO of Myriad Genetics will lead a discussion looking at the decision and the obvious effect it has had on Myriad's falling stock prices.

On 'decision day' Myriad saw its stocks fall by as much as 7% when patents on two human genes associated with breast and ovarian cancer were revoked. The company remains confident that the verdict will not have a material impact on its operations, and with 180 remaining patents unchallenged they are confident in the company's future. But are we to believe the PR Hype? The recent amendment of a company's ability to hold patents over human genes does not just affect Myriad hence why Jeffrey will be joined by such esteemed colleagues as Paul Davis, VP Research and Development Abbott Laboratories



Press Releases

- [Cholesterol Self-Testing Technology Making Strides as Economic and Demographic Trends Foster Increased Demand](#)
- [Quit, Please - Patient Zone Hopes Hospitals Can Slow the Healing Process and Release Cost Factors and Risks](#)

[Home](#) » [Community](#) » [More](#) » [Healthcare Reform](#) » Pharmaceutical Industry Emerges as winners in the Healthcare Reform !

Pharmaceutical Industry Emerges as winners in the Healthcare Reform !

Thursday, 22 October 2009 05:51 |   

[Healthcare Reform](#) - [Healthcare Reform](#)

Pharmaceutical Leaders are set to meet at the anticipated NGP US Summit Next week to discuss reform.

Once a powerful profit-machine, big pharma is stumbling, the threat of further government intervention, drying product pipelines, fierce competition from generic manufacturers, consumer concerns about safety, and false marketing claims is forcing leaders to revisit operations to secure top line Growth. So leaders such as Judith Marquis, Group VP Genzyme, Jeffrey Nye, Chief Medical Officer J&J Pharmaceuticals and James Kirwin VP Global Clinical Operation Wyeth Pharmaceuticals are uniting with over 50 other figureheads at the renowned NGP US Summit next week in Florida to discuss future technology investments to strengthen the industry and improve efficiency to "weather the Healthcare Reform".

Search 29,814 articles from 2,488 suppliers


 [Search](#)

[Homepage](#) »
 [Supplier-R](#) »
 [Next Generation Pharmaceuticals](#)

[First visit to Laboratorytalk?](#) |
 [RSS feeds](#) |
 [Submit your news](#) |
 [Become an advertiser](#) |
 [Newsletter sign up](#)

Browse by category

- Analytical instruments (8984)
- Life sciences and clinical laboratory equipment (4108)
- Computer hardware (860)
- Industry news (28)
- Laboratory equipment and stores (8686)
- Laboratory supplies and consumables (1413)
- Pumps, Valves, Filters (772)
- Services (2226)
- Computer software (3118)



[Company Profile](#) |
 [Company Articles](#)

Key to icons

-  Video
-  Product news
-  Application news
-  Company news
-  Downloads
-  Technical Articles

Next Generation Pharmaceuticals

Technical Articles

- [Pharmaceutical companies to attend NGP summit](#)

Featured articles

Ocean Optics launches Smart-pH Electrodes



Ocean Optics has developed proprietary air gel coating materials that have enabled new technology

Pharmaceutical Industry Set to Emerge as winners in the Healthcare Reform

Pharmaceutical Leaders are set to meet at the anticipated NOP US Summit Next week to discuss reform

Once a powerful profit-machine, big pharma is stumbling, the threat of further government intervention, drying product pipelines, fierce competition from generic manufacturers, consumer concerns about safety, and false marketing claims is forcing leaders to revisit operations to secure top line Growth. So leaders such as Judith Margus, Group VP Genzyme, Jeffrey Nye, Chief Medical Officer J&J Pharmaceuticals and James Kirwin VP Global Clinical Operation Wyeth Pharmaceuticals are uniting with over 50 other figureheads at the renowned NOP US Summit next week in Florida to discuss future technology investments to strengthen the industry and improve efficiency to "weather the Healthcare Reform".

Thomas Haverly - Global VP, Global Clinical Research, Schering-Plough is set to start proceedings and our sources tell us he will be talking about Responding to 21st Century Drug Development Challenge.

"While healthcare reform has dominated headlines, drug companies have come through the debate relatively untouched, but they need to invest wisely to strengthen under the inevitable changes," Drew Contessa NOP US Summit Director.

The good news for the pharmaceutical industry is that it may emerge as a winner in the healthcare reform battle as new customers enter the system and price protections remain in force. IMS Health, the drug industry forecasting firm, reports that the global pharmaceutical industry will grow 4% to 6% in 2010, up to \$925 billion.

Recent Forum Topics

- [Big Pharma conclude M&A is not the new R&D](#)
- [Pharmaceutical Industry Set to Emerge as winners in the Healthcare Reform](#)
- [Healthcare leaders to bridge gaps in preparation for Obama's reform](#)
- ["No Frills Drugs" push Pharmaceutical companies to look for a cure](#)
- [Obama reform resuscitates Healthcare leaders to fix core systems](#)

[more](#)

Pharmaceutical Industry News

[- Bextra](#)